Review Article

Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS

Table 1

PROactive primary end-point results [4].

HR (95% CI)

Death0.96 (0.78–1.18)
Nonfatal MI0.83 (0.65–1.06)
Stroke0.81 (0.61–1.07)
Major leg amputation1.01 (0.58–1.73)
Acute coronary syndrome0.78 (0.55–1.11)
Coronary revascularization0.88 (0.72–1.08)
Leg revascularization1.25 (0.90–1.73)